Bortezomib in the management of multiple myeloma

References

• McKennaRWKyleRAKuehlWMGroganTMHarrisNLCouplanRWPlasma Cell NeoplasmsSwedlowSHCampoEHarrisNLWHO Classification of tumors of haematopoietic and lymphoid tissuesLyonInternational Agency for Research on Cancer2008
   Google Scholar
• JemelASiegelRWardEHaoYXuJMurrayTCancer StatisticsCA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• BarlogieBShaughnessyJEpsteinJPlasma Cell MyelomaLichtmanMABeutlerEKippsTJSeligsohnUKaushanskyKPrchalJTWilliams Hematology7th edNew YorkMcGraw-Hill2005 p.
   Google Scholar
• AlexanianRBarlogieBDixonDHigh dose glucocorticoid treatment of resistant myelomaAnn Intern Med198610518113717812
   PubMed Web of Science ®Google Scholar
• GertzMAGartonJPGreippPRWitzigTEKyleRAA phase II study of high-dose methylprednisolone in refractory or relapsed multiple myelomaLeukemia1995912211521188609725
   PubMed Web of Science ®Google Scholar
• OkenMMHarringtonDPAbramsonNKyleRAKnopseWGlickJHComparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma – Results of Eastern Cooperative Oncology Group Study E2479Cancer1997798156115679118039
   PubMed Web of Science ®Google Scholar
• BarlogieBSmithLAlexanianREffective treatment of advanced multiple myeloma refractory to alkylating agentsN Engl J Med198431021135313566546971
   PubMed Web of Science ®Google Scholar
• AndersonHScarffeJHRansonMVAD chemotherapy as remission induction for multiple myelomaBr J Cancer19957123263307841049
   PubMed Web of Science ®Google Scholar
• GertzMAKalishLAKyleRAHahnRGTormeyDCOkenMMPhase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group studyAm J Clin Oncol19951864754808526187
   PubMed Web of Science ®Google Scholar
• LokhorstHMMeuwissenOJBastEJDekkerAWVAD chemotherapy for refractory multiple myelomaBr J Haematol198971125302644970
   PubMed Web of Science ®Google Scholar
• PhillipsJKSherlaw-JohnsonCPearceRA randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myelomaLeuk Lymphoma1995175–64654727549839
   PubMed Web of Science ®Google Scholar
• BarlogieBHallRZanderADickeKAlexanianRHigh-dose melphalan with autologous bone marrow transplantation for multiple myelomaBlood1986675129813013516252
   PubMed Web of Science ®Google Scholar
• BarlogieBAlexanianRDickeKAHigh-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myelomaBlood19877038698723304465
   PubMed Web of Science ®Google Scholar
• MyungJKimKBCrewsCMThe ubiquitin-proteasome pathway and proteasome inhibitorsMed Res Rev200121424527311410931
   PubMed Web of Science ®Google Scholar
• HideshimaTRichardsonPChauhanDThe proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cellsCancer Res20016173071307611306489
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDRichardsonPNF-kappa B as a therapeutic target in multiple myelomaJ Biol Chem200227719166391664711872748
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSRichardsonPGThe proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood200310162377238012424198
   PubMed Web of Science ®Google Scholar
• HideshimaTMitsiadesCAkiyamaMMolecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood200310141530153412393500
   PubMed Web of Science ®Google Scholar
• ObengEACarlsonLMGutmanDMHarringtonWJJrLeeKPBoiseLHProteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cellsBlood2006107124907491616507771
   PubMed Web of Science ®Google Scholar
• DongHChenLChenXDysregulation of unfolded protein response partially underlies proapoptotic activity of bortezomib in multiple myeloma cellsLeuk Lymphoma200950697498419391038
   PubMed Web of Science ®Google Scholar
• HideshimaTChauhanDHayashiTProteasome Inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myelomaOncogene200322528386839314627979
   PubMed Web of Science ®Google Scholar
• KyleRAGertzMAWitzigTEReview of 1027 patients with newly diagnosed multiple myelomaMayo Clin Proc2003781213312528874
   PubMed Web of Science ®Google Scholar
• LentzschSEhrlichLARoodmanGDPathophysiology of multiple myeloma bone diseaseHematol Oncol Clin North Am200721610351049viii17996587
   PubMed Web of Science ®Google Scholar
• GiulianiNRizzoliVRoodmanGDMultiple myeloma bone disease: Pathophysiology of osteoblast inhibitionBlood2006108133992399616917004
   PubMed Web of Science ®Google Scholar
• TerposEHeathDJRahemtullaABortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myelomaBr J Haematol2006135568869217107351
   PubMed Web of Science ®Google Scholar
• TerposESezerOCroucherPDimopoulosMAMyeloma bone disease and proteasome inhibition therapiesBlood200711041098110417494860
   PubMed Web of Science ®Google Scholar
• ZavrskiIKrebbelHWildemannBProteasome inhibitors abrogate osteoclast differentiation and osteoclast functionBiochem Biophys Res Commun2005333120020515936724
   PubMed Web of Science ®Google Scholar
• MukherjeeSRajeNSchoonmakerJAPharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceJ Clin Invest2008118249150418219387
   PubMed Web of Science ®Google Scholar
• DeleuSLemaireMArtsJBortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myelomaCancer Res200969135307531119531653
   PubMed Web of Science ®Google Scholar
• PennisiALiXLingWKhanSZangariMYaccobySThe proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivoAm J Hematol200984161418980173
   PubMed Web of Science ®Google Scholar
• OrlowskiRZStinchcombeTEMitchellBSPhase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignanciesJ Clin Oncol200220224420442712431963
   PubMed Web of Science ®Google Scholar
• RichardsonPGBarlogieBBerensonJA phase 2 study of bortezomib in relapsed, refractory myelomaN Engl J Med2003348262609261712826635
   PubMed Web of Science ®Google Scholar
• JagannathSBarlogieBBerensonJA phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBr J Haematol2004127216517215461622
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMWBortezomib or high-dose dexamethasone for relapsed multiple myelomaN Engl J Med2005352242487249815958804
   PubMed Web of Science ®Google Scholar
• RichardsonPGSonneveldPSchusterMExtended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialBlood2007110103557356017690257
   PubMed Web of Science ®Google Scholar
• MaMHYangHHParkerKThe proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agentsClin Cancer Res2003931136114412631619
   PubMed Web of Science ®Google Scholar
• OrlowskiRZNaglerASonneveldPRandomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progressionJ Clin Oncol200725253892390117679727
   PubMed Web of Science ®Google Scholar
• PalumboAGayFBringhenSBortezomib, doxorubicin and dexamethasone in advanced multiple myelomaAnn Oncol20081961160116518326520
   PubMed Web of Science ®Google Scholar
• Pineda-RomanMZangariMvan RheeFVTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myelomaLeukemia20082271419142718432260
   PubMed Web of Science ®Google Scholar
• MitsiadesNMitsiadesCSPoulakiVMolecular sequelae of proteasome inhibition in human multiple myeloma cellsProc Natl Acad Sci U S A20029922143741437912391322
   PubMed Web of Science ®Google Scholar
• RichardsonPJagannathSJakubowiakALenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerabilitywith correlation of outcome and adverse cytogenetics in a phase II studyAmerican Society of Hematology Annual Meeting2008 Abstract 1742.
   Google Scholar
• San MiguelJFSchlagRKhuagevaNKBortezomib plus melphalan and prednisone for initial treatment of multiple myelomaN Engl J Med2008359990691718753647
   PubMed Web of Science ®Google Scholar
• HarousseauJLMathiotCAttalMBortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM2005/01 trialAmerican Society of Clinical Oncology Annual Meeting2008 Abstract 8505.
   Google Scholar
• CavoMTacchettiPPatriarcaFSuperior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myelomaAmerican Society of Hematology, Annual Meeting2008 Abstract 158.
   Google Scholar
• SonneveldPVan der HoltBSchmidt-WolfIFirst analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treartment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM)American Society of Hematology Annual Meeting2008 Abstract 653.
   Google Scholar
• RichardsonPLonialSJakubowiakALenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II studyAmerican Society of Hematology, Annual Meeting2008 Abstract 92.
   Google Scholar
• RichardsonPLonialSJakubowiakALenalidomide, bortezomib, and dexamethasone has notable activity in high-risk first-line myeloma. 2009 International Myeloma Workshop; 2009 Abstract 224.
   Google Scholar
• National Comprehensive Cancer NetworkNCCN clinical practice guidelines in oncology. Multiple Myeloma. v.2.2009 URL: www.nccn.org.
   Google Scholar
• RichardsonPGBarlogieBBerensonJClinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myelomaBlood200510692977298116020506
   PubMed Web of Science ®Google Scholar
• JagannathSRichardsonPGSonneveldPBortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trialsLeukemia200721115115717096017
   PubMed Web of Science ®Google Scholar
• ChangHTrieuYQiXXuWStewartKAReeceDBortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myelomaLeuk Res200731677978216996589
   PubMed Web of Science ®Google Scholar
• SagasterVLudwigHKaufmannHBortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletionLeukemia200721116416817096015
   PubMed Web of Science ®Google Scholar
• BladeJFernandez-LlamaPBoschFRenal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institutionArch Intern Med199815817188918939759684
   PubMedGoogle Scholar
• Chanan-KhanAAKaufmanJLMehtaJActivity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective studyBlood200710962604260617138816
   PubMed Web of Science ®Google Scholar
• WechalekarADLachmannHJOfferMHawkinsPNGillmoreJDEfficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseHaematologica200893229529818245653
   PubMed Web of Science ®Google Scholar
• ArgyriouAAIconomouGKalofonosHPBortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literatureBlood200811251593159918574024
   PubMed Web of Science ®Google Scholar
• CavalettiGNobile-OrazioEBortezomib-induced peripheral neurotoxicity: still far from a painless gainHaematologica200792101308131018024368
   PubMed Web of Science ®Google Scholar
• RichardsonPGBriembergHJagannathSFrequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomibJ Clin Oncol200624193113312016754936
   PubMed Web of Science ®Google Scholar
• BadrosAGoloubevaODalalJSNeurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literatureCancer200711051042104917654660
   PubMed Web of Science ®Google Scholar
• PackerLKraemerKRimbachGMolecular aspects of lipoic acid in the prevention of diabetes complicationsNutrition2001171088889511684397
   PubMed Web of Science ®Google Scholar
• De GrandisDAcetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short reviewCNS Drugs200721Suppl 13943 discussion 5–617696592
   PubMed Web of Science ®Google Scholar
• ColvinLAJohnsonPRMitchellRFleetwood-WalkerSMFallonMFrom bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, mentholJ Clin Oncol200826274519452018802169
   PubMed Web of Science ®Google Scholar
• ClearyJFThe pharmacologic management of cancer painJ Palliat Med20071061369139418095817
   PubMed Web of Science ®Google Scholar
• LonialSWallerEKRichardsonPGRisk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myelomaBlood20051063777378416099887
   PubMed Web of Science ®Google Scholar
• SmithLCBertolottiPCurranKJenkinsBGastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership BoardClin J Oncol Nurs200812Suppl 3375218490256
   PubMed Web of Science ®Google Scholar
• ArvinAMVaricella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipientsBiol Blood Marrow Transplant20006321923010871147
   PubMed Web of Science ®Google Scholar
• SchuttPBrandhorstDStellbergWPoserMEbelingPMullerSImmune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infectionsLeuk Lymphoma20064781570158216966269
   PubMed Web of Science ®Google Scholar
• Chanan-KhanASonneveldPSchusterMWStadtmauerEAFaconTHarousseauJLAnalysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyJ Clin Oncol200826294784479018711175
   PubMed Web of Science ®Google Scholar
• BlancoBPerez-SimonJASanchez-AbarcaLIBortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokinesBlood200610793575358316282346
   PubMed Web of Science ®Google Scholar
• MasedaDMeisterSNeubertKHerrmannMVollREProteasome inhibition drastically but reversibly impairs murine lymphocyte developmentCell Death Differ200815360061218188168
   PubMed Web of Science ®Google Scholar
• NeznanovNDragunskyEMChumakovKMDifferent effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replicationPLoS ONE200834e188718382670
   PubMed Web of Science ®Google Scholar
• RichardsonPMitsiadesCColsonKPhase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myelomaLeuk Lymphoma200849350250718297527
   PubMed Web of Science ®Google Scholar
• WeberDBadrosAZJagannathSVorinostat plus bortezomib for the treatment of relapsed/refractory multiple Mmyeloma: early clinical experienceBlood2008102322
   Google Scholar
• BadrosAPhilipSNiesvizkyRPhase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (bort) in relapsed multiple myeloma (MM) patientsAmerican Society of Hematology Annual Meeting2007 Abstract 1168
   Google Scholar
• RichardsonPGChanan-KhanALonialSTanespimycin (T) + bortezomib (bz) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulationAmerican Society of Hematology Annual MeetingBlood2007110 Abstract 1165.
   Google Scholar
• RichardsonPWolfJJakubowiakAPhase I/II results of a multicenter trial of perifosine (KRX-0401) + bortezomib in patients with relapsed or relapsed / refractory multiple myeloma who were previously relapsed from or refractory to bortezomibBlood2008102321
   Google Scholar
• KorethJCutlerCSDjulbegovicBHigh-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trialsBiol Blood Marrow Transplant200713218319617241924
   PubMed Web of Science ®Google Scholar
• BarlogieBTricotGAnaissieEThalidomide and hematopoietic-cell transplantation for multiple myelomaN Engl J Med2006354101021103016525139
   PubMed Web of Science ®Google Scholar
• AttalMHarousseauJLLeyvrazSMaintenance therapy with thalidomide improves survival in patients with multiple myelomaBlood2006108103289329416873668
   PubMed Web of Science ®Google Scholar
• SpencerAPrinceHMRobertsAWConsolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation ProcedureJ Clin Oncol200927111788179319273705
   PubMed Web of Science ®Google Scholar
• MorganGJJacksonGHDaviesFEMaintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisationAmerican Society of Hematology Annual MeetingBlood2008112 Abstract 656.17890457
   PubMedGoogle Scholar
• RichardsonPHofmeisterCCZimmermanTMPhase 1 clinical trial of NPI-0052, a novel proteasome inhibitor in patients with multiple myelomaBlood2008112 Abstract 2770.17890457
   PubMed Web of Science ®Google Scholar
• VijRWangMOrlowskiRInitial results of PX-171-004, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed myeloma (MM)American Society of Hematology, Annual MeetingBlood2008112 Abstract 865.17890457
   PubMedGoogle Scholar
• JagannathSVijRStewartAKInitial results of PX-171-003, an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma (MM)Blood2008112 Abstract 864.17890457
   PubMed Web of Science ®Google Scholar